Trivitron Healthcare is not only a name but a belief for many because of its healthcare innovations and range of medical technology portfolio. Trivitron’s journey started in 1997, with a vision of providing healthcare solutions at affordable costs to a large section of globe. Since then Trivitron as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Having solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. With 13 manufacturing facilities in India, Finland, Turkey, and China and R&D sites in Chennai, Mumbai, Vishakhapatnam, Vantaa (Finland), Vienna (Austria), and Ankara (Turkey), Trivitron spearheads innovation in the fields of new-born screening, in-vitro diagnostics, COVID-19 testing solutions, imaging and radiology, radiation protection, critical care and ICU solutions, and operating room solutions, thus, engraving its name as a holistic healthcare provider.
At Trivitron, we are contributing to the global fight against the coronavirus through our products and expertise in medical technology and healthcare. In our fight against COVID-19, we at Trivitron have been working extensively to bring out solutions for COVID-19 testing, ICU solutions, and personal protection products.
Trivitron has developed rigorous contingency plans to slow the progress of a pandemic and limit its impact on employees, partners, consumers, and communities. Keeping in mind the still-evolving healthcare system of our country, we have scaled-up production to yield more COVID-19 centric products. Trivitron has been a flag-bearer of Make in India and has been working to manufacture COVID-19 related products in its manufacturing facilities in Chennai, Mumbai, and Visakhapatnam. Trivitron Healthcare has been working and made available range of COVID-19 RT-PCR test kits, RNA extraction kits, and specimen collection kits, COVID-19 antigen test kits, PCR systems, and other laboratory products, for COVID-19 diagnosis and confirmation. Trivitron has also started a ventilator manufacturing facility to fulfil the demands of the current healthcare ecosystem. Further to this, Trivitron has also introduced hand sanitizing products, personal protection equipment (PPE), and other required modalities for COVID.
Today, Trivitron Healthcare is a market leader in providing cutting-edge health technology products, which includes a range of diagnostic kits, analyzers, laboratory equipment, radio diagnostic instruments, radiology lab consumables, and radiation protection apparels. In terms of market share, we are seeing considerable growth every fiscal.
We are working on intensified growth strategy to expand our footprints in emerging global markets and plan to acquire more businesses internationally as well as in India. We are the pioneers of new born screening technologies and radiation protection portfolio. Similarly, we have gained a considerable momentum in ICU and critical care product segments. Given the trust of our customers and the acceptance that we are receiving, I am sure we will emerge as a global leader in radiation protection collaterals.
In addition to this, we are doing well in medical imaging and diagnostics, which will continue to be the focus areas for the company, where we are looking for both organic and inorganic growth. Also, we plan to scale up manufacturing abilities to an extent that we become a reliable contract manufacturer for leading healthcare giants. Presently our manufacturing setups are in India, Finland, Turkey, and China and the expansion of our manufacturing plants in US is in the pipeline.
Talking of future, we want to make Trivitron a truly global enterprise offering best healthcare services at affordable prices as per the needs in every continent. Under the banner of Trivitron we want to make cutting edge health technology accessible to all by using our wide network of channel partners and by localizing our manufacturing capabilities. We are hugely investing in R&D, next-gen technologies and expanding our R&D footprint from developing countries to developed countries.